Compare Stocks: MYGN, DGX, EXAS, and NTRA

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
DGX Quest Diagnostics	$236.75 -1.1%	$227.64	$171.18 ▼ $247.19	$26.17B	0.55	844,347 shs	798,698 shs
EXAS Exact Sciences	$104.91	$103.67	$38.81 ▼ $104.98	$20.03B	1.41	3.55 million shs	N/A
MYGN Myriad Genetics	$3.19 -1.2%	$4.43	$2.74 ▼ $8.59	$305.12M	1.68	1.57 million shs	805,852 shs
NTRA Natera	$328.18 +0.2%	$292.62	$157.43 ▼ $343.18	$47.31B	1.54	1.40 million shs	968,061 shs

The Best Nuclear Energy Stocks to Buy

Nuclear energy is entering a new growth cycle as rising power demand, expanding data centers, and renewed policy support bring the sector back into focus. After strong gains in recent years, the most impactful phase of nuclear investment may still be ahead. This report highlights seven nuclear energy stocks positioned across the value chain—combining near-term revenue with long-term upside as next-generation technologies scale. Click the link below to unlock the full list.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
DGX Quest Diagnostics	-1.19%	-2.62%	+0.42%	+17.94%	+32.03%
EXAS Exact Sciences	0.00%	0.00%	0.00%	0.00%	+112.93%
MYGN Myriad Genetics	-1.24%	+0.95%	+1.27%	-30.20%	-53.09%
NTRA Natera	+0.16%	+0.59%	+19.52%	+52.42%	+95.89%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
DGX Quest Diagnostics	$236.75 -1.1%	$227.64	$171.18 ▼ $247.19	$26.17B	0.55	844,347 shs	798,698 shs
EXAS Exact Sciences	$104.91	$103.67	$38.81 ▼ $104.98	$20.03B	1.41	3.55 million shs	N/A
MYGN Myriad Genetics	$3.19 -1.2%	$4.43	$2.74 ▼ $8.59	$305.12M	1.68	1.57 million shs	805,852 shs
NTRA Natera	$328.18 +0.2%	$292.62	$157.43 ▼ $343.18	$47.31B	1.54	1.40 million shs	968,061 shs

The Best Nuclear Energy Stocks to Buy

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
DGX Quest Diagnostics	-1.19%	-2.62%	+0.42%	+17.94%	+32.03%
EXAS Exact Sciences	0.00%	0.00%	0.00%	0.00%	+112.93%
MYGN Myriad Genetics	-1.24%	+0.95%	+1.27%	-30.20%	-53.09%
NTRA Natera	+0.16%	+0.59%	+19.52%	+52.42%	+95.89%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
DGX Quest Diagnostics	2.54	Moderate Buy	$235.31	-0.61% Downside
EXAS Exact Sciences	1.95	Reduce	$98.21	-6.38% Downside
MYGN Myriad Genetics	1.57	Reduce	$3.60	12.85% Upside
NTRA Natera	2.82	Moderate Buy	$319.38	-2.68% Downside

Current Analyst Ratings Breakdown

Latest MYGN, DGX, EXAS, and NTRA Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
9/1/2026	MYGN Myriad Genetics	Piper Sandler Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Overweight ➝ Underweight	$5.45 ➝ $2.00
8/18/2026	MYGN Myriad Genetics	Stephens Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Lower Price Target	Equal Weight	$5.00 ➝ $3.00
8/13/2026	NTRA Natera	Citigroup Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Buy	$315.00 ➝ $365.00
8/12/2026	DGX Quest Diagnostics	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Buy (B+) ➝ Buy (A-)
8/12/2026	NTRA Natera	Stephens Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Overweight	$305.00 ➝ $350.00
8/12/2026	NTRA Natera	Guggenheim Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Buy	$290.00 ➝ $360.00
8/12/2026	NTRA Natera	Zacks Research Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Strong Sell ➝ Hold
8/12/2026	NTRA Natera	Piper Sandler Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Overweight	$249.00 ➝ $363.50
8/10/2026	NTRA Natera	Morgan Stanley Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Overweight	$355.00
8/7/2026	NTRA Natera	TD Cowen Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Buy	$325.00 ➝ $340.00
8/7/2026	NTRA Natera	Royal Bank Of Canada Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Outperform	$275.00 ➝ $350.00

(Data available from 9/5/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
DGX Quest Diagnostics	$11.04B	2.37	$15.15 per share	15.63	$70.84 per share	3.34
EXAS Exact Sciences	$3.25B	6.17	$1.27 per share	82.83	$12.58 per share	8.34
MYGN Myriad Genetics	$824.50M	0.37	$3.75 per share	0.85	$3.18 per share	1.00
NTRA Natera	$2.31B	20.51	N/A	N/A	$12.64 per share	25.96

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
DGX Quest Diagnostics	$992M	$9.42	22.29	19.78	2.17	9.18%	16.01%	7.27%	10/20/2026 (Estimated)
EXAS Exact Sciences	-$207.95M	-$1.10	N/A	209.82	2.02	-6.40%	0.53%	0.22%	N/A
MYGN Myriad Genetics	-$365.90M	-$1.19	N/A	N/A	N/A	-13.96%	-16.09%	-8.10%	11/2/2026 (Estimated)
NTRA Natera	-$208.16M	-$1.36	N/A	32,818.00	N/A	-7.11%	-11.38%	-7.87%	11/5/2026 (Estimated)

Latest MYGN, DGX, EXAS, and NTRA Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/6/2026	Q2 2026	NTRA Natera	-$0.4939	-$0.47	+$0.0239	-$0.47	$661.24 million	$752.75 million
7/30/2026	Q2 2026	MYGN Myriad Genetics	-$0.0579	-$0.25	-$0.1921	-$0.46	$206.03 million	$190.70 million
7/23/2026	Q2 2026	DGX Quest Diagnostics	$2.82	$3.12	+$0.30	$2.84	$2.97 billion	$3.04 billion

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
DGX Quest Diagnostics	$3.44	1.45%	+7.34%	36.52%	14 Years
EXAS Exact Sciences	N/A	N/A	N/A	N/A	N/A
MYGN Myriad Genetics	N/A	N/A	N/A	N/A	N/A
NTRA Natera	N/A	N/A	N/A	N/A	N/A

Latest MYGN, DGX, EXAS, and NTRA Dividends

Announcement	Company	Period	Amount	Yield	Ex-Dividend Date	Record Date	Payable Date
8/12/2026	DGX Quest Diagnostics	quarterly	$0.86	1.45%	10/6/2026	10/6/2026	10/21/2026

(Data available from 1/1/2013 forward)

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
DGX Quest Diagnostics	0.72	1.59	1.46
EXAS Exact Sciences	0.97	2.43	2.17
MYGN Myriad Genetics	0.40	2.21	1.98
NTRA Natera	N/A	3.00	2.85

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
DGX Quest Diagnostics	88.06%
EXAS Exact Sciences	88.82%
MYGN Myriad Genetics	99.02%
NTRA Natera	99.90%

Insider Ownership

Company	Insider Ownership
DGX Quest Diagnostics	0.88%
EXAS Exact Sciences	1.20%
MYGN Myriad Genetics	1.90%
NTRA Natera	5.05%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
DGX Quest Diagnostics	57,000	110.37 million	109.40 million	Optionable
EXAS Exact Sciences	7,200	190.89 million	188.60 million	Optionable
MYGN Myriad Genetics	2,700	95.65 million	93.83 million	Optionable
NTRA Natera	6,140	144.14 million	136.87 million	Optionable

MYGN, DGX, EXAS, and NTRA Headlines

Recent News About These Companies

Nykredit A S Purchases Shares of 57,455 Natera, Inc. $NTRA

September 5 at 5:11 AM | marketbeat.com

Natera (NASDAQ:NTRA) CEO Sells $545,041.02 in Stock

September 4 at 6:37 AM | insidertrades.com

Insider Selling: Natera (NASDAQ:NTRA) CEO Sells 1,698 Shares of Stock

September 3 at 11:06 PM | marketbeat.com

Natera (NASDAQ:NTRA) Insider Sells 3,000 Shares

September 3 at 11:06 PM | marketbeat.com

Natera (NASDAQ:NTRA) Insider Sells 15,160 Shares of Stock

September 3 at 11:06 PM | marketbeat.com

Natera, Inc. $NTRA Shares Sold by Nwam LLC

September 3 at 5:20 AM | marketbeat.com

Natera, Inc. $NTRA Position Trimmed by Braidwell LP

September 3 at 4:39 AM | marketbeat.com

Jupiter Topco LLC Buys Shares of 10,826 Natera, Inc. $NTRA

September 3 at 3:51 AM | marketbeat.com

Natera, Inc. Announces Clinical Validation Of Signatera For MRD Assessment In Lymphoma

September 2 at 7:02 PM | marketscreener.comM

Why Moderna's Cancer Vaccine Matters to Investors

September 2 at 12:04 PM | etftrends.comE

New Publication Establishes Strong Clinical Validation of Signatera™ for MRD Assessment in Lymphoma

September 1, 2026 | businesswire.com